posted
Wait until ARCA moves on. He still has a few more shares to get rid of and as you can see he is sitting * .023 This should reverse nicely when the selling is done
Posts: 145 | From: Canada | Registered: Sep 2006
| IP: Logged |
posted
Looks like they increased their shares recently. This is a great bottom play. Alot of people are getting in and waiting for the move before putting it out there. Been watching this like a hawk. It's getting close.
Posts: 145 | From: Canada | Registered: Sep 2006
| IP: Logged |
from 10KSB: **** We have not generated any revenues and our operating activities have used cash resources of $2,179,209 for the fiscal year ended June 30, 2006. This negative cash flow is attributable to our operation expenses, including but not limited to, research and development expense and the payment of our audit fees and legal fees. We anticipate that our operating expenses will increase as we intend to conduct detailed development of our first product - hematopoietic stem cells, animal pre-clinical trials and experiments and clinical trials and work towards its completion. We estimate our expenses in the next twelve months will be approximately $2,600,000, generally falling in two major categories: research and development costs and general and administrative expenses. **** We do not expect to generate any revenues in the next twelve months. Our products will likely not be ready for sale for at least five years, if at all. ****
Posts: 1580 | From: World | Registered: Jul 2006
| IP: Logged |
posted
Pluristem Pre-Clinical Results: Placenta Expanded Cell Therapy Product Increases Umbilical Cord Blood Engraftment up to 500% in Bone Marrow Transplants
By BusinessWire Last Update: 10/16/2006 7:31:10 AM Data provided by
HAIFA, Israel, Oct 16, 2006 (BUSINESS WIRE) -- Pluristem Life Systems, Inc. (PLRS), a cell therapy company dedicated to the commercialization of stem cell products, announces promising final results of an animal model study which could benefit 100,000 blood cancer patients annually. PLX-I, the Company's innovative adjuvant cell therapy product is based on Placenta Expanded Mesenchymal cells. It intended to resolve the global shortfall of matched tissue for blood cancer patients requiring bone marrow transplantation by improving the engraftment of Umbilical Cord Blood (UCB). The Pre-Clinical results document that adding Pluristem's PLX-I to UCB stem cells during the Bone Marrow Transplant (BMT) human cell engraftment in NOD SCID mice showed up to a 500% increased engraftment after irradiation and Chemotropic treatment.
BMT traditionally treats patients whose bone marrow has been damaged by chemotherapy, or certain genetic diseases that lead to anemia, leukemia, lymphomas, autoimmune disease and other blood-related disorders. Its effectiveness is severely limited because of the lack of a matching donor or shortage of UCB stem cells engrafted during the procedure. If additional animal studies and human clinical trials prove equally successful as this first Pre-Clinical, Pluristem's PLX-I product with 500% increased engraftment could lead to more Bone Marrow Transplants (BMT) for these types of blood cancers.
The animal studies were performed on immune-deficient NOD SCID mice following systemic myeloablation of their bone marrow to simulate the BMT clinical protocol. This in-vivo model is based on the known ability of human Hematopoietic Stem Cells (HSC) to engraft in mouse bone marrow and to simulate the recovery of the human's Hematological system. 50,000-100,000 human UCB derived CD34+ cells (hUCB CD34+) were injected into the tail vein of NOD-SCID mice along with 0.5*106 PLX I cells. After periods of 28-32 days, mice were sacrificed and the marrow was analyzed. Human cell engraftment was performed in both sub lethally irradiated (350 Rad) and chemotherapy administrated (50 mg/kg Busulfan) mice. FACS analysis of human CD45 positive cells in mice bone marrow demonstrated an increscent of cell engraftment in part of the experimental animals up to 5 folds compared to mice transplanted with CD34+ cells only.
Mr. Zami Aberman, CEO, stated, "Co-transplantation of PLX-I cell types may be a promising manipulation improving cord blood performance during the bone marrow transplants in adults blood disorder. The pre-clinical results suggest blood disorder treatment is being improved by using MSC derived from placenta and expanded in Pluristem's 3D bioreactor in combination with UCB derived HSC. We strongly believe that PLX-I can change the clinical process now being used to treat blood cancer and could eventually save millions of lives."
About Pluristem
Pluristem Life Systems, Inc. is a life sciences driven company that is developing and commercializing stem cell expansion technology products for the treatment of severe blood disorders. The Company is discovering and developing cell-based therapeutics that utilizes adult stem cells expanded in a proprietary bioreactor mimicking different naturally occurring physiological environments. Pluristem expects its first products to be cell grafts that will provide an efficient and superior alternative to the standard procedure of bone marrow transplantation. Its first adult stem cell product targets a critical global shortfall of matched tissue for bone marrow transplantation since bone marrow transplantation is often the only cure for patients suffering from leukemia, lymphoma, myeloma and many other hematological diseases. The Company has made a strategic decision to work only with adult stem cells since the practical use of embryonic stem cells is severely restricted by various religious, ethical and legal considerations.
This press release contains statements, which may constitute "forward-looking statements" regarding our intent, belief or current expectations. Forward-looking statements in this release include statements: results of our animal model study could benefit 100,000 blood cancer patients annually; that PLX-1 is intended to resolve the global shortfall of matched tissue for blood cancer patients requiring bone marrow transplantation by improving the engraftment of Umbilical Cord Blood (UCB); that if additional animal studies and human clinical trials prove equally successful as this first Pre-Clinical, Pluristem's PLX-I product with 500% increased engraftment could lead to more Bone Marrow Transplants (BMT) for these types of blood cancers; the pre-clinical results suggest blood disorder treatment is being improved by using MSC derived from placenta and expanded in Pluristem's 3D bioreactor in combination with UCB derived HSC; and we believe that PLX-I can change the clinical process now being used to treat blood cancer and could eventually save millions of lives. Factors which may significantly change or prevent our forward looking statements from fruition include that we may be unsuccessful in developing any products; that our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; that pre-clinical trials results may not be able to be successfully duplicated in clinical trials; that we are unable to retain or attract key employees whose knowledge is essential to the development of our products; that unforeseen scientific difficulties develop with our process; that results in the laboratory do not translate to equally good results in real surgical settings; that our patents are not sufficient to protect essential aspects of our technology; that competitors may invent better technology; that our products may not work as well as hoped or worse, that our products may harm recipients; and that we may not be able raise funds for development or working capital when we require it. As well, our products may never develop into useful products and even if they do, they may not be approved for sale to the public. For further risk factors see the Company's latest 10-KSB filed with the SEC.
SOURCE: Pluristem Life Systems, Inc.
Posts: 204 | Registered: Feb 2006
| IP: Logged |
posted
I am not in this one, but has an awesomely respectable chart. It is holding STRONGGGGGG
Posts: 1220 | From: Denver, CO | Registered: Jun 2005
| IP: Logged |
quote:Originally posted by before_the_crowd: Very Interesting...Chart.. Volume Huge but not much movement today.... Gotta look into it....
CDs have to be covered - think almost done... Another day with 30-40 million and it will take off...
Posts: 1580 | From: World | Registered: Jul 2006
| IP: Logged |
quote:Originally posted by before_the_crowd: Very Interesting...Chart.. Volume Huge but not much movement today.... Gotta look into it....
CDs have to be covered - think almost done... Another day with 30-40 million and it will take off...
with an additional 20 million in trades CDs will be wiping out... Even with 50% of mirror trades 4.5 - 5 cents to EOW look highly positive... eom
Posts: 1580 | From: World | Registered: Jul 2006
| IP: Logged |
posted
here is some PLRS i found on another message board:
kirkdog7: PLRS is going to become the biggest play in the entire OTC BB market!!!!!!!!!!!
The US Government just came out yesterday and said they are earmarking $14 million for umbilical cord blood banks because they believe it will cure blood cancer and save millions of lives.
In order for the umbilical cord blood to take the place of Bone Marrow Transplants, you need PLRS's technology!!!!!!!!!
BUZZ!!! kirkdog7: PLRS=50 million served today! and the day is still young! BUZZ!!! kirkdog7: smart--gonna make BANK !!! kirkdog7: .028 X .028 now kirkdog7: something BIG supposed to happen FRIDAY kirkdog7: .029 X .029 and watch for Friday kirkdog7: more than a 3-day tour!! could be a life changer!!! ggg ggg: agreed kirkdog7: 67 million already served today!!!!!!!!!!!!
-------------------- please dont trade stocks on my alerts, do your dd first. Posts: 5265 | From: Alberta | Registered: Jan 2006
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
